McMaster University enhances partnership with University of Saskatchewan in fight against COVID-19, future pandemics
Hamilton’s McMaster University has enhanced its long-standing collaboration with the University of Saskatchewan in the fight against COVID-19 and future pandemics.
A partnership agreement was signed, bringing the two institutions together to accelerate vaccine and drug development, human and animal clinical trials, and create new diagnostic tools.
According to an official announcement by McMaster on Thursday (Feb. 25), the partnership will leverage the extensive research facilities and industry partnerships at Canada's Global Nexus for Pandemics and Biological Threats, based at McMaster, and the University of Saskatchewan's Vaccine and Infectious Disease Organization (VIDO).
"The complex challenges of pandemics will only be solved by this type of partnership," says Gerry Wright, lead, Canada's Global Nexus for Pandemics and Biological Threats.
"Canada's Global Nexus and VIDO's research strengths, which span human and animal health, are deep and complementary and by bringing together our collective expertise, global networks and industry partnerships, we have the strength and track record to protect Canadians from COVID-19 and future pandemics."
Both institutions are considered among the only Canadian centres with the specialized containment facilities, equipment and research expertise necessary to quickly isolate pathogens including SARS-CoV-2 (the virus that causes COVID-19), ramp up vaccine discovery and manufacturing, and identify new and emerging threats including variants of viruses such as COVID-19.
"Collaboration is essential to rapidly respond to emerging infectious diseases," said VIDO director and CEO Dr. Volker Gerdts.
"As a Centre for Pandemic Research, VIDO is glad to collaborate with Canada's Global Nexus to leverage our complementary scientific expertise and infrastructure to help prepare Canada for the next pandemic."
The agreement establishes a formal scientific exchange between the University of Saskatchewan and McMaster in infectious disease research, vaccine and drug development, and evidence-based information to guide decision-makers and new policies.
It will also create training opportunities for postdoctoral fellows and graduate students.
Specific areas of collaboration include:
- developing and testing new vaccines and drug candidates
- production of vaccines and clinical trials for humans and animals
- development of new diagnostics and other ways of identifying known and emerging infectious agents
- development of animal models for emerging infectious diseases and
Both institutions have also partnered with numerous pharmaceutical and biotechnology companies to advance COVID-19 solutions.
- Hamilton's McMaster research team developing COVID-19 vaccine that can be inhaled
- McMaster researchers work to develop second-gen COVID-19 vaccines in Hamilton
- McMaster University-led team studying COVID-19 drug treatment
- McMaster researchers look to prevent future long-term care outbreaks after $5M funding from feds
- Canadian-made COVID-19 vaccine approved for clinical trials by Health Canada
- 401 closed as Mississauga woman killed in early morning collision
- Dump truck protest rolls onto highways in Mississauga and Brampton
- Alarming new record of COVID-19 cases set today in Mississauga and Brampton
- Brampton truck driver charged for smuggling cocaine into Canada
- 65% of all Mississauga and Brampton residents will have the vaccine by early June